<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C., 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
JANUARY 2, 1997
Date of Report (Date of earliest event reported)
NASTECH PHARMACEUTICAL COMPANY INC.
(Exact Name of Registrant as Specified in Charter)
<TABLE>
<S> <C> <C>
DELAWARE 0-13789 11-2658569
(State or other jurisdiction of (Commission File No.) (I.R.S. Employer Identification No.)
incorporation or organization)
</TABLE>
45 DAVIDS DRIVE, HAUPPAUGE, NEW YORK, 11788
(Address of Principal Executive Offices)
(516) 273-0101
(Registrant's telephone number, including area code)
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.
On January 2, 1997, the appointment of Robbins, Greene, Horowitz,
Lester & Co., LLP as independent auditors for the Registrant was terminated by
the Registrant and KPMG Peat Marwick LLP was engaged as independent auditors.
The decision to change independent auditors was approved by the Audit Committee
and Board of Directors of the Registrant. During the fiscal years ended June
30, 1995 and 1996, and the subsequent interim period through January 2, 1997,
there were no disagreements between the Registrant and Robbins, Greene,
Horowitz, Lester & Co., LLP on any matter of accounting principles or
practices, financial statement disclosure, or auditing scope or procedures
which disagreements if not resolved to the satisfaction of Robbins, Greene,
Horowitz, Lester & Co., LLP would have caused them to make reference to the
subject matter of the disagreement in connection with their report.
The audit reports of Robbins, Greene, Horowitz, Lester & Co., LLP on
the Registrant's financial statements as of and for the years ended June 30,
1995 and 1996, did not contain an adverse opinion or a disclaimer of opinion,
nor were they qualified or modified as to uncertainty, audit scope, or
accounting principles.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
<PAGE> 2
NASTECH PHARMACEUTICAL COMPANY INC.
-----------------------------------
(Registrant)
By: /s/ Dr. Vincent D. Romeo
-------------------------------
DR. VINCENT D. ROMEO, President
and Chief Executive Officer
DATED: January 3, 1997
EXHIBIT INDEX
16.0 Letter on change of certifying accountant pursuant to Item 304(a)(3)
of Regulation SB
<PAGE> 1
ROBBINS, GREENE, HOROWITZ, LESTER & CO., LLP
Certified Public Accountants
Members 310 Madison Avenue
American Institute of New York, NY 10017
Certified Public Accountants Tel (212)808-4280
New York State Society of Fax (212)697-4486
Certified Public Accountants
January 3, 1997
Securities and Exchange Commission
Washington, D.C. 20549
We were previously principal accountants for Nastech Pharmaceutical
Company Inc. and on August 15, 1996, we reported on the financial statements of
Nastech Pharmaceutical Company Inc. as of and for the two years ended June 30,
1996. On January 2, 1997, we were dismissed as principal accountants of Nastech
Pharmaceutical Company Inc. We have read Nastech Pharmaceutical Company Inc.'s
statements included under Item 4 of its Form 8-K for January 2, 1997, and we
agree with such statements.
Very truly yours,
/s/ ROBBINS, GREENE, HOROWITZ, LESTER & CO., LLP
-------------------------------------------------
ROBBINS, GREENE, HOROWITZ, LESTER & CO., LLP
